Symberix Featured in Nature Reviews Article on Small Molecule Microbiome Therapeutics

Durham, NC (July 12, 2019) - Symberix is profiled in a new Nature Reviews article on companies developing microbiome-modulating small-molecule drugs. The article highlights our novel therapeutic approach and includes quotes from our co-founder and Chief Scientific Officer, Dr. Matt Redinbo.

The full article is published at Nature Reviews Drug Discovery.

Greg Mossinghoff
Chief Business Officer
Symberix, Inc.